Skip to main content
. 2004 Feb 3;90(3):626–631. doi: 10.1038/sj.bjc.6601587

Figure 1.

Figure 1

Tumour cell proliferation marker Ki-67 (MIB-1) LI in patients with mRCC (A) before and (B) after 1 month of interleukin-2- and interferon-α-based immunotherapy for patients obtaining partial response (PR), stable disease (SD) and progressive disease (PD). The box plots represent the median, the 25th and the 75th percentiles, respectively. The error bars represent the 10th and the 90th percentiles, respectively.